Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCAS phase II trial of lazertinib plus pemetrexed/carboplatin after prior lazertinib failure in EGFR-mutant NSCLC
KCT0008198Phase 2Completed
- Sponsor
- Yuhan
- Start
- Apr 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lazertinib, pemetrexed and carboplatin in non-small cell lung cancer (NSCLC), sponsored by Yuhan. Primary endpoint: Progression-free survival. Started Apr 2023; status: completed.
02
Drugs
lazertinibpemetrexedcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0008198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008198.